AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 FEB 11 - (NewsRx.com & NewsRx.net) -- The Dow Chemical Company (DOW) has entered into a 4-year, $5.7 million cooperative research agreement from the U.S. National Institutes of Health (NIH) to apply new technology for rapid development of vaccines.
Dow will subcontract with Fraunhofer USA Center for Molecular Biotechnology to codevelop the technology, and with the University of Maryland to provide screening for efficacy.
NIH requested proposals for new vaccine technologies against infectious diseases, including biowarfare agents. Dow's approach will be based on new plant viral particle technology, with vaccine protein production taking place on leaves of greenhouse-grown plants.
Speed of production is the most significant advantage according to Carolyn Fritz, Dow's global business director for Industrial ...